代谢功能障碍相关脂肪性肝病(MASLD)影响肝细胞癌根治性手术后长期结局
这项回顾性队列研究纳入柏林夏里特医学院2010至2020年间因肝细胞癌接受肝切除或原位肝移植的579例患者,分析病因、复发时间、总生存及CT体成分。结果显示肝切除后MASLD病因患者总生存显著短于其他病因,MASLD是总生存的独立预后因素。
要点
- 肝切除后MASLD病因患者中位总生存63个月,短于其他病因的80个月。
- MASLD患者中位复发时间26个月,与其他病因的30个月无显著差异。
- MASLD病因、门静脉血栓和MELD评分≥10是肝切除后总生存的独立预后因素。
核心结论
- 接受肝切除且符合新MASLD标准的肝细胞癌患者总生存显著缩短。
- 该研究为新型MASLD/MetALD分类提供了预后证据。
研究设计与样本
- 回顾性队列研究,纳入柏林夏里特医学院2010至2020年间因肝细胞癌接受肝切除或原位肝移植的患者。
- 共579例肝细胞癌患者,其中417例接受肝切除,162例接受原位肝移植。
主要发现
- 肿瘤病因:病毒性191例(33.0%),MASLD 158例(27.3%),MetALD 51例(8.8%),ALD 68例(11.7%),其他/隐源性111例(19.2%)。
- MASLD和MetALD患者较非代谢功能障碍病因患者有更多肌肉内脂肪(p < 0.001,p = 0.015)和内脏脂肪(均p < 0.001)。
- 肝切除后MASLD-HCC患者中位复发时间26个月(95% CI:23-31)与其他病因30个月(95% CI:4-57)相比无显著差异(p = 0.425)。
- 肝切除后MASLD-HCC患者中位总生存63个月(95% CI:42-84)短于其他病因80个月(95% CI:60-100),风险比1.53(95% CI:1.050-2.229),p = 0.026。
- 多因素分析证实MASLD病因、门静脉血栓和MELD评分≥10是肝切除后总生存的独立预后因素(校正p = 0.021,p < 0.001,p = 0.003),排除院内死亡后仍显著(校正p = 0.016,p = 0.002,p = 0.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Curative surgery for hepatocellular carcinoma (HCC) includes liver resection (LR) and orthotopic liver transplantation (OLT). Due to the obesity epidemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is a frequent HCC aetiology that often coincides with increased alcohol consumption, termed MetALD, or even alcohol-associated liver disease (ALD). METHODS: Patients undergoing LR or OLT for HCC at Charité-Universitätsmedizin Berlin (2010-2020) were included in this retrospective cohort study investigating disease aetiology, time to recurrence (TTR), overall survival (OS) and CT-based body composition. RESULTS: Out of 579 patients with HCC, 417 underwent LR and 162 OLT. Tumour aetiologies were viral n = 191 (33.0%), MASLD n = 158 (27.3%), MetALD n = 51 (8.8%), ALD n = 68 (11.7%) and other/cryptogenic n = 111 (19.2%). Patients with MASLD and MetALD had more intramuscular (p < 0.001, p = 0.015) and visceral fat (both p < 0.001) than patients with non-metabolic dysfunction aetiologies. Patients with MASLD-HCC had comparable TTR (median 26 months, [95% CI: 23-31] vs. 30 months [95% CI: 4-57], p = 0.425) but shorter OS than patients with other HCC aetiologies (63 months [95% CI: 42-84] vs. 80 months [95% CI: 60-100], hazard ratio: 1.53 [95% CI: 1.050-2.229], p = 0.026) after LR. Multivariate analysis confirmed MASLD aetiology, portal vein thrombosis and MELD score ≥ 10 as independent prognostic factors for OS in LR (adjusted p = 0.021,p < 0.001,p = 0.003), even after excluding in-hospital mortality (adjusted p = 0.016,p = 0.002,p = 0.002). Causes of death were similar in MASLD and non-MASLD aetiology. CONCLUSIONS: Patients with HCC undergoing LR and meeting the new MASLD criteria have significantly shorter OS. This study provides empirical prognostic evidence for the novel MASLD/MetALD classification in a large European cohort of patients undergoing curative-intent HCC therapy.
引用
- Uluk D, Pein J, Herda S, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Impacts Long-Term Outcomes After Curative-Intent Surgery for Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2025. PMID: 39964081. doi:10.1111/apt.70002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。